๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xiangtan
Clinical trial register · China

Clinical Trials in Xiangtan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Xiangtan

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events
NCT07748039Acute Ischemic Stroke, Large Vessel Occlusion, Anterior Circulation Brain Infarction
Yongjun Wang
Phase 3
1,440
Beijing, Wuhan, Xiangtan, Rizhao, Ya'an
2026-08-01
Not yet open
Safety and Efficacy Evaluation of an Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy (CMPA)
NCT07484035Cow's Milk Protein Allergy (CMPA)
Heilongjiang Feihe Dairy Co. Ltd.
Not applicable
124
Beijing, Foshan, Zhuhai, Xiangtan, Wuxi, Chengdu
2026-03-05
Recruiting
To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
NCT07208591Acute Respiratory Distress Syndrome (ARDS)
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Active, closed
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT07220109Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
NCT06987305Stroke, Acute Ischemic
Xinqiao Hospital of Chongqing
Phase 3
820
Wuhan, Xiangtan, Jiujiang, Nanchang
2025-10-21
Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT07145229Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Atom Therapeutics Co., Ltd
Phase 2
380
Beijing, Nanning, Langfang, Wuhan, Xiangtan, Zhuzhou, Huai'an, Pingxiang
2025-08-26
Recruiting
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair
NCT06998680Alopecia, Canities
Vita Green Pharmaceutical (H.K.) Ltd.
Not applicable
152
Xiangtan
2025-07-30
Recruiting
Endovascular Treatment for eXtra-Large Ischemic Stroke
NCT06388148Stroke, Acute Ischemic
Zhongming Qiu
Not applicable
286
Hengyang, Xiangtan
2024-06-16
Recruiting
Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
NCT05604638Acute Ischemic Stroke
Second Affiliated Hospital of Guangxi Medical University
Phase 3
348
Chuzhou, Longyan, Nanning, Huanggang, Yichang, Huaihua, Shaoyang, Xiangtan
2024-04-24
Recruiting
Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
NCT06210633Acute Ischemic Stroke (AIS), Acute Ischemic Stroke From Large Vessel Occlusion
Zhongming Qiu
Observational
1,000
Xiangtan
2024-01-20
Recruiting
Post-market European & Asian Registry to Evaluate the Minosโ„ข Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech๏ผˆGroup๏ผ‰Co., Ltd
Observational
200
Lanzhou, Meizhou, Shenzhen, Changsha, Xiangtan, Yueyang, Zibo, Binhai
2023-03-05
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/xiangtan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Xiangtan.

How many clinical trials are recruiting in Xiangtan?

8 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xiangtan), 11 studies
PhaseStudiesRecruitingShare
Phase 35345.5%
Not applicable3227.3%
Observational2218.2%
Phase 2119.1%

Most active sponsors

Lead sponsors with the most studies (Xiangtan)
Lead sponsorStudiesRecruiting
Zhongming Qiu22
Atom Therapeutics Co., Ltd11
GlaxoSmithKline10
Heilongjiang Feihe Dairy Co. Ltd.10
Second Affiliated Hospital of Guangxi Medical University11
Shanghai MicroPort Endovascular MedTech๏ผˆGroup๏ผ‰Co., Ltd11
Staidson (Beijing) Biopharmaceuticals Co., Ltd11
Vita Green Pharmaceutical (H.K.) Ltd.11
Xinqiao Hospital of Chongqing11
Yongjun Wang10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.